ID   T47D Ad60
AC   CVCL_ZZ25
DR   cancercelllines; CVCL_ZZ25
DR   Wikidata; Q102114963
RX   PubMed=8562478;
RX   PubMed=9815641;
CC   Population: Caucasian.
CC   Doubling time: 86.0 hours (PubMed=8562478; PubMed=9815641).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0553 ! T-47D
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 6
//
RX   PubMed=8562478;
RA   Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M.,
RA   Gudas J.M., Bates S.E.;
RT   "Normal p53 status and function despite the development of drug
RT   resistance in human breast cancer cells.";
RL   Cell Growth Differ. 6:1395-1403(1995).
//
RX   PubMed=9815641;
RA   Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.;
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//